IL17A and infection: Second, the quality of most evidence (except high-quality evidence for secukinumab versus placebo, moderate-quality evidence for anti-IL-17 agents versus anti-IL-12/23 agents for Candida infection, and guselkumab versus placebo for serious infections) was found to be low or very low.